The company operates a three-star hotel and restaurant in Surat, Gujarat, and holds licenses for the retail and wholesale trade of foreign liquor and wine.
The company lacks a durable moat, as evidenced by a low average ROCE of 7.3% and stagnant revenue growth. While it possesses specific liquor licenses in a restricted state, these do not translate into pricing power or superior returns, and the business remains a small-scale commodity player in a competitive hospitality market.
Capital allocation is poor, with earnings largely reinvested into a low-return business or held in low-yield assets. The company has failed to generate meaningful incremental returns on equity, and dividends have been withheld to conserve resources for a business that is barely growing.
Five years later, the investment has halved because the company remained a 'cigar butt' with no puff left. The capital trapped in this low-return hospitality asset was slowly eroded by inflation and stagnant revenues, while the promoter-controlled entity continued to siphon value through related-party liquor transactions. The transition to a sole-proprietorship auditor preceded a breakdown in financial oversight, and the lack of pricing power meant the business could not pass on rising operating costs, leading to a slow-motion liquidation of shareholder value through mediocrity.
RichFakir rates H. S. India Ltd's business quality as poor — 27/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, H. S. India Ltd is trading about 38% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on H. S. India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of H. S. India Ltd's fair value is about ₹8 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →